Syros Pharmaceuticals stock (US8719201096): Delisting to OTC triggers investor attention

Syros Pharmaceuticals, Inc. (SYRS) has undergone a significant corporate action with its delisting from Nasdaq to over-the-counter (OTC) markets. According to the Robinhood Corporate Actions Tracker as of May 2026, SYRS shares were transitioned to OTC trading. This development reduces exchange listing requirements but may affect trading volume and institutional interest for retail investors.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Syros Pharmaceuticals: core business model

Syros Pharmaceuticals focuses on developing novel therapeutics for oncology and rare diseases by mapping gene regulation to drive drug discovery. The company's proprietary platform identifies novel targets and drug candidates, targeting transcription factors to alter gene expression in diseased cells. This approach aims to address unmet needs in cancers like AML and breast cancer.

Headquartered in Lexington, Massachusetts, Syros advances clinical-stage programs including tamibarotene, a RAR? agonist for NPM1-mutant AML. The business model relies on milestone payments, collaborations, and potential commercialization, with key partnerships enhancing its pipeline development.

Main revenue and product drivers for Syros Pharmaceuticals

Syros' revenue stems primarily from collaboration agreements and research funding. Key drivers include partnerships with pharmaceutical giants for co-development, providing upfront payments and royalties. The tamibarotene program, in Phase 2 trials, represents a major value driver, with potential regulatory milestones ahead.

Pipeline progress, such as SELECT-MDS trial data published in prior periods (Q4 2024 earnings as of Syros IR site), supports investor focus. For US investors, exposure to innovative biotech plays in the oncology space ties into broader market trends in precision medicine.

Industry trends and competitive position

The biotech sector faces volatility from clinical trial outcomes and funding environments, yet oncology remains a high-growth area. Syros differentiates through its gene control platform amid rising demand for targeted therapies. Competitors like Incyte and Takeda in RAR? space highlight the competitive landscape.

US market relevance grows with FDA priorities on rare disease drugs, positioning Syros for potential accelerated approvals relevant to domestic portfolios.

Why Syros Pharmaceuticals matters for US investors

As a US-listed biotech (now OTC), Syros offers exposure to cutting-edge oncology R&D without direct international risks. Its pipeline aligns with US healthcare spending on cancer treatments, exceeding $200 billion annually per sector data.

Conclusion

The delisting of Syros Pharmaceuticals to OTC reflects ongoing corporate adjustments in the biotech space, potentially signaling strategic shifts amid clinical advancements. Investors monitor pipeline updates and liquidity impacts. Developments continue to evolve.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.